Member Info for tqhussain

this is one crazy share. reacts to every buy or sell

bob mac (director), he just added 100000

http://moneyam.uk-wire.com/cgi-bin/articles/201011011137293645V.html

does anyone know how much does one of these machines sell for?

http://www.vectura.com/products/pipeline.aspx

back in at 56p GLA

looking very good for the future

Update on NVA237 and QVA149 & Achievement of a development milestone for VR632 Chippenham, UK - 21 October 2010: Vectura Group plc (LSE: VEC) ("Vectura") acknowledges an announcement by Novartis as part of its quarterly earnings update today that Novartis expects the chronic obstructive pulmonary disease (COPD) products, NVA237 and QVA149, to launch in 2012 and 2013 respectively. Vectura also announces today that it has achieved a milestone in relation to progress made with the inhaled generic combination asthma and COPD product, VR632, from Sandoz AG, the generics division of Novartis. Update on NVA237 / QVA149 Novartis have today provided an update on NVA237 and QVA149 as part of their Q3, 2010 results presentation. Key points of note from the presentation include: · NVA237 and QVA149 have expected launch dates of 2012 and 2013 respectively · An announcement of NVA237 Phase III data in COPD is anticipated in Q2, 2011 NVA237 was licensed to Novartis by Vectura and its co-development partner Sosei in a 2005 deal in which the two companies could receive up to US$375 million in milestones as well as royalties on product sales. QVA149 is a once-daily, dry powder bronchodilator for inhalation combining a fixed dose of the once-daily beta2-agonist QAB149 (indacaterol) and the long-acting muscarinic antagonist NVA237 (glycopyrronium bromide) for the treatment of COPD. Phase III trials for NVA237 and QVA149 commenced in June 2009 and May 2010 respectively. Novartis received European regulatory approval for indacaterol (Onbrez® Breezhaler® - indacaterol maleate) in November 2009 with the initial launch of the product in Germany in December 2009. US approval is subject to the FDA's review of additional clinical data that Novartis filed at the end of September 2010. VR632 milestone achievement VR632 is being developed as a generic combination product using Vectura's GyroHaler® dry powder inhaler (DPI) delivery device. It is the second inhaled combination therapy for asthma/COPD being jointly developed with Sandoz in Europe in addition to VR315. As well as today's VR632 milestone of €0.6m, Vectura expects to receive the final VR632 development milestone in 2011 with approval milestones following thereafter. Vectura has achieved all the development milestones due for VR315 and is currently awaiting approval milestones for that product. Dr Chris Blackwell, Chief Executive of Vectura: "Vectura's franchise in the respiratory sector now has four products with a clear path through to market. Novartis' publication of its expected launch dates for NVA237 and QVA149 confirms that these two major value drivers are progressing to plan. This, together with progress being made on both VR315 and VR632, demonstrates the near-term value of these products to Vectura's shareholders."

profit taking i think

wont let me buy, been trying for 10 mins

can you see any other reason why directors would have bought shares this year? does your doc friend have any insight in to this? thanks

A lot Director buys this year that could mean good phase 3 results Cancer drug developer Antisoma will soon report data from two important clinical trials: a phase III study of AS1413 and a phase IIb study of AS1411. The AS1413 trial is most critical because positive data would lead to submissions for marketing authorisations. CEO, Glyn Edwards says: "We are on track to report pivotal trial results for AS1413 in the first half of next year. "If these are positive, we will file marketing applications. Our latest market research suggests that AS1413 could generate very substantial sales revenues." Antisoma forecasts that peak global sales of AS1413 could reach $670m per annum if it gains initial approvals for treatment of patients with secondary acute myeloid leukaemia (AML) and subsequent approvals for use in older 'de novo' AML patients. With approvals in secondary AML alone, the Company would expect expect global peak sales in the range of $440 to $580m.

with a small punt

thanks, hope he has all the success at Northgate. Motorhome travel sounds fun. I can only dream of having 6 months off, lol (got a day job) Enjoy your travels and drive safe!

http://www.fleetnews.co.uk/news/2010/10/11/northgate-vehicle-hire-continues-to-invest-in-new-vehicles/37906/

Just doing a bit of research on the financials and i have to say NTG is looking very good. Admittedly i didnt know much about the company when i bought last year (was new to trading) but now i'll keep these locked away in my ISA for another 6-12 months.

same here, today was the first time i saw a northgate van.

Hi, does your brother still work for NTG? if so would it be possible for you to get an insight in to the business health. Thanks you for your input the last time, it was reassuring.

Its been a very positive recovery in the SP since the last set of positive results. I was thinking of selling a few months back at a 40% loss but thanks to some advice of some kind people on this board i held and now only 17% down.

yes it looks like it. the contract is twice the size of the market cap, be it over 5 years. current Sp should move closer to 15p IMO